CBD Reduced Seizures in Most Children with Drug-Resistant Epilepsy

In a retrospective review of 50 children with drug-resistant epilepsy (mostly Lennox-Gastaut syndrome), CBD as add-on therapy produced complete seizure response (>90% reduction) in 10 children, partial response (30-90% reduction) in 18, and no response in 14. Eight children became entirely seizure-free. Adverse effects occurred in 44% but none required hospitalization. Eight children discontinued treatment.

Retrospective chart review of children with drug-resistant epilepsy who received CBD for at least six months at a single center. Assessed seizure frequency reduction, parent-reported adverse effects, and discontinuation rates. Epilepsy types included Lennox-Gastaut syndrome (n=32), Dravet syndrome (n=4), and tuberous sclerosis complex (n=2).

Drug-resistant epilepsy leaves families with few options. This real-world data from a clinical setting supports the growing evidence that CBD can meaningfully reduce seizures in children who have not responded to standard treatments.

CBD (as Epidiolex) is already FDA-approved for certain seizure disorders. Studies like this one extend the evidence base to broader clinical practice, showing consistent results outside of controlled trial settings.

Retrospective design without a control group. Single center. Parent-reported outcomes subject to recall bias. No standardized dosing protocol described. Heterogeneous epilepsy types grouped together.